| Inclusion Criteria: | 1) Patients with solid gastrointestinal tumors or lung cancer patients referred to palliative care and a 5% or more involuntary weight loss within the last 6 months with anorexia (>3 on visual analog scale such as ESAS)
2) Greater than or equal to 18 years of age
3) Karnofsky score of 40 or higher
4) Patient has the ability to maintain oral food intake during the study period
5) Patients who have persistent anorexia/cachexia and are currently taking a stable dose of Megace, corticosteroids, non-steroidal anti-inflammatories (NSAID'S), or thalidomide and started at least 2 weeks prior to study inclusion
6) Ability to sign informed consent and understand study procedures
7) Patient can continue all medications including complementary therapies or antineoplastic therapy while on-study other than melatonin if they have been on stable dose for at least 2 weeks
8) Negative pregnancy testing in women with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
9) Patients who cannot take Megace because of past history or elevated risk of DVT, adrenal insufficiency, impotence, hyperglycemia, CHF, menorrhgia, etc.
10) Patients who have persistent anorexia/cachexia after treatment with Megace has failed |